On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis U.S. LLC’s (“Sanofi”) MERILOG™ (insulin-aspart-szjj), a biosimilar to Novo Nordisk A/S’s (“Novo Nordisk”) ...
Technological advancements in insulin pens, pumps, and continuous glucose monitoring systems have greatly improved the convenience and effectiveness of rapid acting insulin. Current delivery devices ...
A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...
MyChesCo on MSN
FDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for Millions Battling Diabetes
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first ...
ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
On Feb. 14, the agency approved the drug, a biosimilar to Novolog, for glycemic control improvement in adult and pediatric diabetic patients. The subcutaneous medication is approved in a 3 milliliter, ...
More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...
DUBLIN--(BUSINESS WIRE)--The "Global Rapid Acting Insulin Market By Product Type, By Indication, By Distribution Channel, By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027" ...
Please provide your email address to receive an email when new articles are posted on . Technsophere insulin conferred a similar HbA1c as a rapid-acting analog for children and adolescents with ...
Rise in availability of continuous glucose monitoring and surge in investments in R&D for human recombinant insulin drive the growth of the global rapid acting insulin market. PORTLAND, Ore., April 22 ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback